197 related articles for article (PubMed ID: 35368048)
1. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
Clesham K; Walf-Vorderwülbecke V; Gasparoli L; Virely C; Cantilena S; Tsakaneli A; Inglott S; Adams S; Samarasinghe S; Bartram J; Williams G; de Boer J; Williams O
Leukemia; 2022 Jun; 36(6):1541-1549. PubMed ID: 35368048
[TBL] [Abstract][Full Text] [Related]
2. Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
Walf-Vorderwülbecke V; Pearce K; Brooks T; Hubank M; van den Heuvel-Eibrink MM; Zwaan CM; Adams S; Edwards D; Bartram J; Samarasinghe S; Ancliff P; Khwaja A; Goulden N; Williams G; de Boer J; Williams O
Leukemia; 2018 Apr; 32(4):882-889. PubMed ID: 29089643
[TBL] [Abstract][Full Text] [Related]
3. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
Armenteros-Monterroso E; Zhao L; Gasparoli L; Brooks T; Pearce K; Mansour MR; Martens JHA; de Boer J; Williams O
Leukemia; 2019 Dec; 33(12):2817-2829. PubMed ID: 31138842
[TBL] [Abstract][Full Text] [Related]
4. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
[TBL] [Abstract][Full Text] [Related]
5. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
Elife; 2021 Feb; 10():. PubMed ID: 33527899
[TBL] [Abstract][Full Text] [Related]
6. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
Klempnauer KH
Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
[TBL] [Abstract][Full Text] [Related]
7. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
8. Peptidomimetic blockade of MYB in acute myeloid leukemia.
Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
[TBL] [Abstract][Full Text] [Related]
9. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
10. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
Zuber J; Rappaport AR; Luo W; Wang E; Chen C; Vaseva AV; Shi J; Weissmueller S; Fellmann C; Taylor MJ; Weissenboeck M; Graeber TG; Kogan SC; Vakoc CR; Lowe SW
Genes Dev; 2011 Aug; 25(15):1628-40. PubMed ID: 21828272
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways.
Gan S; Ma P; Ma J; Wang W; Han H; Chen L; Li X; Wu F; Sun H
Eur J Pharmacol; 2019 Feb; 844():38-48. PubMed ID: 30502345
[TBL] [Abstract][Full Text] [Related]
12. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
[TBL] [Abstract][Full Text] [Related]
15. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
[TBL] [Abstract][Full Text] [Related]
16. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia.
Zhao H; Jin S; Gewirtz AM
J Biol Chem; 2012 Jan; 287(2):925-34. PubMed ID: 22110127
[TBL] [Abstract][Full Text] [Related]
17. Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.
Schmidt TJ; Klempnauer KH
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408476
[TBL] [Abstract][Full Text] [Related]
18. A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia.
Xu Y; Milazzo JP; Somerville TDD; Tarumoto Y; Huang YH; Ostrander EL; Wilkinson JE; Challen GA; Vakoc CR
Cancer Cell; 2018 Jan; 33(1):13-28.e8. PubMed ID: 29316427
[TBL] [Abstract][Full Text] [Related]
19. Transcription Factor MYB as Therapeutic Target: Current Developments.
Klempnauer KH
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542205
[TBL] [Abstract][Full Text] [Related]
20. c-myc and c-myb expression in acute myelogenous leukemia.
Gopal V; Hulette B; Li YQ; Kuvelkar R; Raza A; Larson R; Goldberg J; Tricot G; Bennett J; Preisler H
Leuk Res; 1992 Oct; 16(10):1003-11. PubMed ID: 1405703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
